Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries ATHIRA ALERT: Bragar Eagel & Squire, P.C. Is Investigating Athira Pharma, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm By: Bragar Eagel & Squire, P.C. via Business Wire May 20, 2022 at 21:00 PM EDT Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Athira Pharma, Inc. (NASDAQ: ATHA) on behalf of long-term stockholders following a class action complaint that was filed against Athira on June 25, 2021 with a Class Period from September 17, 2020 through June 17, 2021. Our investigation concerns whether the board of directors of Athira have breached their fiduciary duties to the company. Click here to participate in this action. On June 17, 2021, after the markets closed, Athira announced that the company's board had placed its president and CEO, Leen Kawas, on temporary leave pending their investigation of "actions stemming from doctoral research Dr. Kawas conducted while at Washington State University." According to one investment analyst, the scientific basis for Athira came out of the work Kawas and her colleagues developed at Washington State and this news could have "clear negative implications for how we/investors view the asset, and/or management credibility." Healthcare news outlets also cited concerns that images in academic articles published by Kawas could have been manipulated. On this news, Athira's stock price fell $7.09 per share, or nearly 39%, to close at $11.15 per share on June 18, 2021, on unusually heavy trading volume. If you are a long-term stockholder of Athira, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. View source version on businesswire.com: https://www.businesswire.com/news/home/20220520005465/en/Contacts Bragar Eagel & Squire, P.C. Brandon Walker, Esq. Melissa Fortunato, Esq. (212) 355-4648 investigations@bespc.com www.bespc.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
ATHIRA ALERT: Bragar Eagel & Squire, P.C. Is Investigating Athira Pharma, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm By: Bragar Eagel & Squire, P.C. via Business Wire May 20, 2022 at 21:00 PM EDT Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Athira Pharma, Inc. (NASDAQ: ATHA) on behalf of long-term stockholders following a class action complaint that was filed against Athira on June 25, 2021 with a Class Period from September 17, 2020 through June 17, 2021. Our investigation concerns whether the board of directors of Athira have breached their fiduciary duties to the company. Click here to participate in this action. On June 17, 2021, after the markets closed, Athira announced that the company's board had placed its president and CEO, Leen Kawas, on temporary leave pending their investigation of "actions stemming from doctoral research Dr. Kawas conducted while at Washington State University." According to one investment analyst, the scientific basis for Athira came out of the work Kawas and her colleagues developed at Washington State and this news could have "clear negative implications for how we/investors view the asset, and/or management credibility." Healthcare news outlets also cited concerns that images in academic articles published by Kawas could have been manipulated. On this news, Athira's stock price fell $7.09 per share, or nearly 39%, to close at $11.15 per share on June 18, 2021, on unusually heavy trading volume. If you are a long-term stockholder of Athira, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. View source version on businesswire.com: https://www.businesswire.com/news/home/20220520005465/en/Contacts Bragar Eagel & Squire, P.C. Brandon Walker, Esq. Melissa Fortunato, Esq. (212) 355-4648 investigations@bespc.com www.bespc.com
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Athira Pharma, Inc. (NASDAQ: ATHA) on behalf of long-term stockholders following a class action complaint that was filed against Athira on June 25, 2021 with a Class Period from September 17, 2020 through June 17, 2021. Our investigation concerns whether the board of directors of Athira have breached their fiduciary duties to the company. Click here to participate in this action. On June 17, 2021, after the markets closed, Athira announced that the company's board had placed its president and CEO, Leen Kawas, on temporary leave pending their investigation of "actions stemming from doctoral research Dr. Kawas conducted while at Washington State University." According to one investment analyst, the scientific basis for Athira came out of the work Kawas and her colleagues developed at Washington State and this news could have "clear negative implications for how we/investors view the asset, and/or management credibility." Healthcare news outlets also cited concerns that images in academic articles published by Kawas could have been manipulated. On this news, Athira's stock price fell $7.09 per share, or nearly 39%, to close at $11.15 per share on June 18, 2021, on unusually heavy trading volume. If you are a long-term stockholder of Athira, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. View source version on businesswire.com: https://www.businesswire.com/news/home/20220520005465/en/
Bragar Eagel & Squire, P.C. Brandon Walker, Esq. Melissa Fortunato, Esq. (212) 355-4648 investigations@bespc.com www.bespc.com